RAAB MICHAEL sold $211K of ARDX

RAAB MICHAEL (President & CEO) sold 41,668 shares of ARDELYX, INC. (ARDX) at $5.06 ($0.21M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAAB MICHAEL
Published Jul 17, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

Because the sale is under a pre-arranged 10b5-1 plan, it is typically treated as lower-signal than discretionary selling, reducing expected fundamental impact.

02

Market read

Traders may note the insider sale for sentiment, but there is no new company-specific catalyst beyond the transaction details.

03

What to watch

The filing does not indicate whether other insiders sold/bought around the same time, nor does it provide context on tax or diversification needs.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-17 after-hours, reflecting a 2026-07-15 sale

Background

The article is an SEC Form 4 insider transaction disclosure for ARDELYX, INC. (ARDX).

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

SEC Form 4 shows ARDX CEO Raab Michael sold 41,668 shares on 2026-07-15 under a 10b5-1 plan for about $210,923.

Expected impact

Likely minimal immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial datapoint.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Insider sales under 10b5-1 can be purely liquidity-driven and may not reflect bearish expectations.

Key entities

  • ARDX

    Ardelyx, Inc., the company whose CEO insider sale is disclosed.

  • RAAB MICHAEL

    President & CEO of Ardelyx, reported open-market sale of shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.